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In December, 1976, while I was a medical student on a
dermatology elective, I saw John Melski cross the Beth Israel
(BI) Hospital parking lot with a black, box-like, briefcase and the
most intense, absorbed expression I had ever seen on a face. In
the briefcase were data forms from the oral methoxsalen
photochemotherapy cooperative clinical trial. That night, as on
many others, John’s wife Linda would teletype the data from their
home to the hospital computer with one hand while she cradled
their baby with the other. Behind Melski’s countenance were no
doubt thoughts of PUVA (photochemotherapy with psoralens plus
ultraviolet A), or, as I recently learned, a growing fear that he
would be buried alive by the mounting stacks of boxes which
contained the PUVA treatment records of more than a thousand
patients. At the time, Melski was a fellow in computer medicine
at the Beth Israel Hospital, Harvard Medical School, working in
the laboratory of Howard Bleich. They had been enlisted to
participate in the design and analysis of a project that is still
ongoing, and which has become one of the largest, longest, and
most careful follow-up studies of a single disease and its treatment
in the history of dermatology. The chief of dermatology at the BI
was Irwin Freedberg, one of the multicenter trial participating
investigators and editor of the Journal of Investigative Dermatology.
According to Melski, Freedberg’s ‘‘clear vision’’ of the JID’s role
in communicating not only to academicians but to practitioners
as well was the single most important reason that it was ultimately
published there. The role model of Freedberg and his ilk was also
what led Melski to become a dermatologist. But we have come to
the end almost before the beginning, and the tale of the
multicenter PUVA trial is one of people, vision, monumental
effort, important notes on napkins, and intrigue, not to mention a
stickup at gunpoint.
The story of the multicenter trial cannot be separated from the
story of PUVA itself, and that goes back no less than 3500 years to
the treatment of vitiligo in ancient Egypt and India [1]. But in the
early 1970s at Massachusetts General Hospital, a group of people
with remarkably complementary interests came together and took
a partly conceptual and partly technological inventive leap that
took psoralens from the pharaohs to Faraday. That leap was the
development of a new high-intensity ultraviolet A (UVA) light
source and its combination with the use of orally administered
methoxsalen in the treatment of psoriasis. Fitzpatrick and Pathak
had been interested in oral psoralens for nearly two decades [2,3].
Parrish, who had just completed his dermatology residency, was
interested in the comparative effects of ultraviolet radiation,
especially UVA, and had finally convinced Robert Levin and the
GTE Sylvania company to make a high intensity UVA light source
to pursue his investigations. Tanenbaum, who had become
interested in photobiology as a medical student by listening to a
guest lecture by Leonard Harber, had some elective time coming
up in his residency at Harvard and wanted to do a research
project he could complete in the last six months of his second
year. Why not try the new light source in looking at oral psoralen
phototoxicity in the treatment of psoriasis and other diseases?
Some basic and clinical groundwork had already been laid by the
Harvard group and others [1]. For example, it was known that
psoralens plus UVA caused inhibition of DNA synthesis.
Mortazawi [4], Tronnier and Schule [5], and Walter and Voorhees
[6] had looked at the use of topical psoralens with longwave UV
in the treatment of psoriasis, and Weber published on the subject
in 1974 [7].
The MGH group, however, tried the new high intensity
ultraviolet A light source with oral 8-MOP on two patients on
White 8, the dermatology ward. The first was a women with
mycosis fungoides, the second a 35-year-old Irish policeman with
psoriasis. Both responded quickly, and cleared dramatically in
10–12 treatments. As luck would have it, both were ideal
candidates with (fair) skin type II and plaque lesions. Had the
first patients been eythrodermic or skin type I, burning might have
nipped the study in the bud. Had they been skin types III or IV,
early tanning might have made the response less impressively
rapid. More patients were treated in succession, some in bilateral
comparison fashion, and the results were striking. Sometime near
the spring of 1974, Fitzpatrick decided to ‘‘export’’ the MGH
experience to Vienna. His former student, Klaus Wolff, agreed to
test the early MGH protocol on a group of Austrian psoriatics.
Before he left for Vienna, Fitzpatrick wrote the following on a
napkin still in Tanenbaum’s possession, ‘‘PHOTOCHEMOTHERAPY
OF EPIDERMAL (psoriasis) AND LYMPHOPROLIFERATIVE DIS-
ORDERS (Mycosis Fungoides) WITH PSORALEN PLUS LONG-
WAVE U.V. (U.V.A.),’’ (Fig 1). The significance of introducing
that term, and of its acronymic sister, PUVA, in casting the die for
what came next cannot be overestimated. Writing of diseases,
Richard Asher said that without a name, a disease ‘‘has no official
clinical existence. We cannot discuss it or investigate it or write
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about it’’ [8]. The same can be said for treatments, and no one can
deny that PUVA has been discussed, investigated, and written
about, probably more than any new treatment in dermatology.
With the napkin came a challenge and target to publish the results
in the New England Journal of Medicine by October. The journal
was full until December, though, which meant that the initial
paper did not appear until the issue of December 5, 1974 [9], and
it was released just as everyone left for the American Academy of
Dermatology annual meeting. According to the New England
Journal’s usual routine, the media had been given preprints by the
journal, and photochemotherapy hit Time magazine and front
pages around the world immediately. It was, according to
Fitzpatrick, ‘‘an overnite success 20 years in the making.’’ This
unfortunate quirk of timing and publicity led to substantial
resentment toward the innovation and the innovators. But it also
probably played at least some role in generating the feeling that a
multicenter trial should be done.
Why was the multicenter PUVA trial organized? When the
need for it was being debated, a prominent Philadelphia
dermatologist reportedly said that anyone who knew anything
about psoriasis and saw the 1974 New England Journal of
Medicine report could tell that photochemotherapy was impor-
tant and worked. (Incidentally, that paper became the second
most frequently cited publication in the history of that journal.)
Why bother? First, the investigators were concerned about the
possibility of long-term side effects. According to Parrish, ‘‘If I was
going to be involved in the introduction of a new treatment, I felt
a responsibility to know what the long-term risks might be, and
you need a large study over a long enough period of time to find
out.’’ Fitzpatrick states that in the back of his mind was his
recollection of what happened at the time compound F
(hydrocortisone) was introduced for the treatment of rheumatoid
arthritis by Kendall and Hench at the Mayo Clinic in 1948. He
had been in the lab next door and remembered Kendall insisting
on a multicenter trial because it would give them ‘‘a faster
answer’’ about whether or not it really worked. The MGH group
was also worried that patients would get hurt if the treatment was
not introduced in a controlled manner, that it would not work if
not done properly, and that such experiences could discredit the
treatment before it even had a chance to prove itself. According to
Fitzpatrick, ‘‘You can give someone the recipe for a souffle but if
it doesn’t come out that doesn’t mean the recipe was bad.’’
A protocol was hammered out, investigators from 16 centers
were enlisted, and Bleich and Melski were recruited to help and
to manage the data. At the time, Bleich had a computer with
one-tenth the memory of what a personal computer has today.
It was also being used to handle his own research and the
hospital’s admitting and medical records. Bleich fondly recollects
that he was ‘‘not aware that dermatologists had such a penchant
for data collection,’’ and that the avalanche of forms (65 feet
when piled) pushed his lab to the limits. The experience not only
‘‘made better computer people out of us,’’ but significantly
strengthened the impetus for the development and use of bigger
computers in medicine.
Once collected and analyzed, the data not only confirmed that
photochemotherapy was a highly effective treatment for psoriasis,
but added several critical new findings. First, no clinically
significant changes in laboratory screening tests or eye examina-
tions attributable to PUVA were detected. Second, the multi-
center trial demonstrated that maintenance treatments were
helpful in sustaining clinical remission of the disease. The
findings were published in the JID in June, 1977 [10], and had
a major impact in no fewer than ten ways.
First, the multicenter trial established that PUVA was an
effective treatment for psoriasis. The fact that it was successful in
16 different sites meant that its utility was not restricted to
research settings, and furthermore, that it was an effective
outpatient option for the management of extensive and refractory
psoriasis. It can be argued that the ultimate acceptance of PUVA
depended substantially on these points. PUVA’s effectiveness was
also soon confirmed in large cooperative studies reported by
Henseler et al in European centers and by Roegnik et al in another
U.S. multicenter trial [11,12].
Second, the trial established that the treatment was safe during
the initial 18-month observation period. Earlier concerns about
potential hepatic side effects were laid to rest, and no eye
abnormalities attributable to PUVA were detected. Concerns
about skin cancer induction remained, but the multicenter trial is
what set the stage for the follow-up study to address them. Robert
Stern has spearheaded this effort. After initial reports in 1979 and
1984 [13,14], the latest results, with 5–10-year follow-up data,
have just appeared in the JID [15]. (Editor’s note: The Editorial
Board continues Irwin Freedberg’s commitment to publication of
important classic clinical studies.)
Third, the publication of the cooperative clinical trial results
provided further justification for National Institutes of Health
funding of the PUVA Follow-up study. Most of the initial funding
had been literally scraped together from a variety of sources,
including large amounts from the Sylvania Lighting Products
Division of GTE. Senior vice president Richard Hodges was
instrumental in Sylvania’s excursion into photomedicine.
Fourth, the PUVA follow-up study, which is still ongoing, has
become the most long-standing and largest follow-up of a cohort
of patients with any dermatologic disease. From it much has been
learned not only about a treatment and its side effects, but about
psoriasis itself [16,17]. The effect of photochemotherapy on the
cost of treatment for psoriasis was also assessed from the follow-
up study [18] and served as an excellent example of how the
impact of a new technology could be assessed. From the start, the
original investigators and subsequent critics have worried about
the lack of a control group. Richard Baughman, one of the
original 28 cooperating investigators, maintains that a placebo
control group would have been impossible for ethical reasons
and because patients would have sought treatment elsewhere.
He also notes that the ‘‘dose response curve’’ obtained from
Figure 1. Napkin on which the term ‘‘photochemotherapy’’ was first written
by Fitzpatrick in 1974 (Courtesy of Lewis Tanenbaum, M.D.).
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the available data has provided much of the kind of information
that might have been hoped for from a different type of study.
According to Baughman, the multicenter trial and follow-up
study also provide a data bank and standard of comparison
by which to measure new therapies such as etretinate and
cyclosporin.
Fifth, the multicenter trial and follow-up study ‘‘brought new
paradigms’’ to dermatology. Stern points out that for the first time,
long-term outcomes rather than mere response to treatment were
assessed, and, consequently, the perspective on psoriasis as a
chronic disease whose treatment required a long view came into
focus. According to Parrish, the persistent motivation to lower
total cumulative exposure to PUVA was an important stimulus to
the development of the concept of combination treatment in
psoriasis utilizing PUVA along with other modalities such as
methotrexate [19], UVB [20], and retinoids [21]. Furthermore,
PUVA’s effectiveness in psoriasis led to its use in many other
disorders, ranging from mycosis fungoides [22] and lichen planus
[23] to graft-versus-host disease [24] and even uncommon
photodermatoses [25]. Most recently, it has led to the develop-
ment of extracorporeal photochemotherapy [26].
Sixth, the multicenter trial enabled the Food and Drug
Administration to address a novel problem for the first time;
namely, the approval of a new technology that utilized a drug,
which they were used to dealing with, and a new device, which
they were not. The history of the FDA’s prolonged deliberations
over PUVA approval is a saga in itself, and therein rests at least
some of the intrigue whose story must be left to a different time
and place. Suffice it to say that without a multicenter trial, PUVA
might well have sunk in a regulatory mire.
Seventh, the convincing introduction of PUVA was a major
impetus in the subsequent development of photomedicine as a
discipline [27]. Madhu Pathak notes that the use of psoralens
to study fundamental questions of nucleic acid chemistry
and photobiology increased exponentially after 1974. PUVA
and photochemotherapy are now both Medical Subject Head-
ings. Using a Grateful Med search of the National Library of
Medicine, I found that from 1986 through the first few months of
1988,107 papers contained PUVA in the title. 178 were indexed
with PUVA as a subject, and 356 were indexed with photo-
chemotherapy as a subject. And look at the number
of dermatology departments throughout the world, including
China and the Soviet Union, that now have photomedicine and
photobiology units.
Eighth, PUVA had a major impact on many investigators’ lives.
Melski credits Fitzpatrick with a ‘‘driving vision’’ of the
impotance of PUVA and what would be required to establish it,
and Parrish with a ‘‘prescient understanding’’ of what PUVA’s
implications might be from the molecular to the societal level.
Fitzpatrick, beeming with pleasure he could barely contain,
pointed to the effect that work on PUVA has had on the lives of
John Parrish, Klaus Wolff, Madhu Pathak, and Robert Stern. He
also pointed to the new Wellman Research Laboratories at the
Massachusetts General Hospital, made possible through the gift of
a grateful MGH PUVA patient, and representing the largest single
gift ever made to that institution. Tanenbaum, now in private
practice, continues to design and coordinate clinical trials as a
consultant medical director for Syntex research. Melski is in the
Dermatology Department at the Marshfield Clinic in Wisconsin,
actively involved in software development and evaluation of
clinical systems in medical computing.
Ninth, as Baughman put it, ‘‘PUVA should be viewed as a
triumph of our specialty.’’ The extent to which its mechanism(s)
of action were understood showed that dermatology was in the
mainstream of molecular medicine. The extent to which they
were not has generated a vast amount of basic research. The
effect that it had on the therapeutic armamentarium against one of
the most common and difficult diseases we encounter, and on
basic research, greatly increased the visibility of our field. Eleven
years after the Melski report, Klaus Wolff wrote, ‘‘In my opinion
this was the best and most thoroughly controlled study ever
published on a therapeutic trial in dermatology up to that date.
Together with the following paper on the European multicenter
trial on roughly 3000 patients published by Henseler et al, this
study is responsible for the fact that PUVA today is the most
thoroughly studied therapeutic modality ever employed in
dermatology.’’ PUVA also intensified the international spirit of
dermatology, with major innovations and collaborations coming
from the entire globe. Wolff, Honigsmann, and their Austrian
colleagues, in particular, have been involved and innovative from
the earliest stages [9,12,21,28,29].
Finally, PUVA has made life liveable for tens of thousands of
people with severe psoriasis. As Harvey Baker wrote in 1984, ‘‘no
dermatologist who looks after patients with severe forms of
psoriasis would like to be without the PUVA weapon’’ [30].
And the stick-up at gunpoint? On a site visit to Stanford in
1975, Tanenbaum was held up in a parking lot. Gun at head, he
‘‘reluctantly’’ relinquished all his money and some PUVA data.
Ten years later, when a new patient from Texas came into his
San Francisco office and asked, ‘‘Do you all do PUVA?’’ the
impact of his work hit home – and the answer (short version)
was, fortunately, ‘‘yes.’’
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